Kyntra Bio Reports Q3 Revenue, Ends FG-3246 Program
The San Francisco biopharmaceutical company posted third quarter 2026 net income after discontinuing two development candidates.
Updated on Nov. 16, 2026 in Finance

Kyntra Bio reported total revenue from continuing operations of $1.8 million and net income from continuing operations of $0.2 million for the third quarter of 2026. The company also discontinued development of FG-3246 and FG-3180 after the FG-3246 Phase 2 study was stopped for insufficient efficacy.
Why it matters
The decision removes two candidates from Kyntra Bio's pipeline and shifts the company's near-term focus toward its approved drug roxadustat. The restructured royalty agreement also reduces a future payment obligation, changing the company's financial commitments.
Kyntra Bio's third quarter 2026 net income of $0.2 million, or $0.04 per share, compares with a net loss of $13.1 million, or $3.25 per share, in the same quarter of 2025. The company's $44.1 million cash and receivables position as of September 30 is expected to fund operations into 2028, though the Phase 3 plan depends on securing a partner or outside capital.
The players
Kyntra Bio
A biopharmaceutical company headquartered in San Francisco that develops and commercializes roxadustat for anemia of chronic kidney disease.
NQ Project Phoebus, L.P.
The counterparty to Kyntra Bio's royalty financing agreement, which received an accelerated upfront payment under the amended deal.
Andrew E. Singer, MBA
A newly appointed member of Kyntra Bio's Board of Directors.
The details
The company closed enrollment in the Phase 2 study of FG-3246 in metastatic castration-resistant prostate cancer and stopped the program after a pre-specified interim analysis showed insufficient efficacy. In August 2026, Kyntra Bio also amended its royalty financing agreement with NQ Project Phoebus, L.P., reducing the maximum aggregate payment obligation by $60 million in exchange for an accelerated upfront payment.
Timeline
August 2026: Kyntra Bio signed the amended royalty financing agreement with NQ Project Phoebus, L.P.
September 30, 2026: The company reported $44.1 million in cash, investments and receivables.
November 16, 2026: Kyntra Bio released its third quarter 2026 financial results.
First quarter of 2027: The company plans to start a pivotal Phase 3 roxadustat trial, subject to a partnership or external capital raise.
Market Landscape
Kyntra Bio's strategy now rests on roxadustat, which is already approved in Europe, Japan, China and numerous other countries for anemia of chronic kidney disease. The company's planned pivotal Phase 3 trial in the United States would be its route to a broader Western market.
Investors in Kyntra Bio now see a company with cash expected to last into 2028 and a narrower pipeline centered on roxadustat. The planned Phase 3 trial depends on a partnership or outside capital, so future dilution or deal terms remain a factor for shareholders.
The takeaway
Kyntra Bio's shift from a multi-candidate pipeline to a single approved drug highlights how biotech companies often concentrate capital after early trial failures. Readers tracking the company should watch whether it secures the partnership needed to start its Phase 3 roxadustat study.
What happens next
Kyntra Bio plans to initiate a pivotal Phase 3 roxadustat trial in the first quarter of 2027, subject to a strategic partnership or external capital raise.
Further reading
For more on company earnings and restructuring, see Corporate Finance.
Source note: This article includes information reported by The Manila times.






